2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals
Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint
Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer

Johnson & Johnson (NYSE:JNJ) today announced results for third-quarter 2026.

"Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio," said Joaquin Duato, Chairman and Chief Executive Officer. "In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade."

Overall financial results

	Q3
($ in Millions, except EPS)	2026	2025	% Change
Reported Sales	$25,399	$23,993	5.9%
Net Earnings	$210	$5,152	(95.9)%
EPS (diluted)	$0.09	$2.12	(95.8)%

	Q3
*Non-GAAP ($ in Millions, except EPS)**	2026	2025	% Change
Operational Sales^1,2			6.0%
Adjusted Operational Sales^1,3			6.1%
Adjusted Net Earnings^1,4	$6,339	$6,801	(6.8)%
Adjusted EPS (diluted)^1,4	$2.59	$2.80	(7.5)%
Free Cash Flow^5,6	~$15,100	$14,226

¹		Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²		Excludes the impact of translational currency
³		Excludes the net impact of acquisitions and divestitures and translational currency
⁴		Excludes intangible amortization expense and special items
⁵		Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
⁶		Third-quarter YTD 2026 is estimated as of October 13, 2026
Note: values may have been rounded

Regional sales results

Q3				% Change
($ in Millions)	2026	2025	Reported	Operational^1,2	Currency	Adjusted Operational^1,3
U.S.	$14,959	$13,708	9.1%	9.1	-	9.1
International	10,440	10,285	1.5	1.8	(0.3)	1.9
Worldwide	$25,399	$23,993	5.9%	6.0	(0.1)	6.1

¹		Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²		Excludes the impact of translational currency
³		Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded

Segment sales results

Q3				% Change
($ in Millions)	2026	2025	Reported	Operational^1,2	Currency	Adjusted Operational^1,3
Innovative Medicine	$16,757	$15,563	7.7%	7.9	(0.2)	8.0
MedTech	8,642	8,430	2.5	2.5	0.0	2.5
Worldwide	$25,399	$23,993	5.9%	6.0	(0.1)	6.1

¹		Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²		Excludes the impact of translational currency
³		Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded

Third-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

October 2026

July 29, 2026

Adjusted Operational Sales^1,2